The Allergan breast implant lawsuit has reached a critical inflection point in 2026. With the first bellwether trial now locked in for October 19, 2026, and AbbVie having reached an agreement in June 2026 to resolve substantially all U.S.-based ALCL lawsuits, plaintiffs and their families are facing a pivotal moment. MDL 2921 — formally titled In re Allergan BIOCELL Textured Breast Implant Products Liability Litigation — is no longer a slow-moving pretrial proceeding. It is a mass tort on the verge of resolution, and that changes everything about how claims are evaluated, how defendants negotiate, and how much time potential claimants have to act.
What Is MDL 2921 and Why Does It Matter in 2026?
MDL 2921 is consolidated before Judge Brian R. Martinotti in the U.S. District Court for the District of New Jersey. As of July 1, 2026, the docket contains 1,261 pending actions — a figure that reflects the ongoing individualized resolution process underway as AbbVie works to address substantially all U.S.-based ALCL claims following its June 2026 agreement. For context, this litigation began in 2019 following the FDA’s Class I recall of Allergan’s BIOCELL textured implants — the most serious category of recall the agency issues. The establishment of a Qualified Settlement Fund under Case Management Order No. 38 in December 2025 has provided a formal administrative structure to manage the flow of resolved claims and support the fund administration process going forward.
The core of the Allergan breast implant lawsuit centers on a rare but serious cancer called Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). Critically, BIA-ALCL is not breast cancer — it is a T-cell lymphoma, classified as a distinct cancer entity by the World Health Organization, that develops in the fluid or scar tissue capsule surrounding the implant rather than in the breast tissue itself. Allergan’s BIOCELL implants account for an estimated 84 to 86 percent of all BIA-ALCL cases reported to the FDA worldwide, a proportion so disproportionate that it forms the bedrock of the scientific case against the company. You can review FDA recall classification standards at the FDA’s official Allergan recall page.
The FDA Class I Recall and the Six-Times Cancer Risk
On July 24, 2019, the FDA issued a Class I recall — its most serious designation — for Allergan’s Natrelle BIOCELL textured breast implants and tissue expanders. The recall followed the agency’s determination that BIOCELL implants carried a six-times higher risk of BIA-ALCL compared to other textured implants on the market. The key culprit identified in the scientific literature is BIOCELL’s proprietary salt-loss macro-texturing process, which creates an aggressively rough surface on the implant shell. Comparative data showed that Allergan’s macro-textured design carried significantly greater cancer risk than competing micro-textured products such as Mentor’s Siltex implants.
Plaintiffs in the Allergan breast implant lawsuit allege that the company was not caught off guard by this connection. According to court filings, Allergan tracked adverse-event reports linking BIOCELL’s surface design to BIA-ALCL for years before the 2019 recall. Central to the litigation is what plaintiffs describe as an eight-year gap between the FDA’s first formal recognition of a BIA-ALCL link in 2011 and the eventual recall in 2019 — a period during which, plaintiffs argue, Allergan allegedly failed to adequately warn patients or take corrective action. The reach of this litigation has not been limited to U.S. courts: in December 2025, judges in Amsterdam rejected a €900 million collective damages claim brought on behalf of approximately 60,000 women in the Netherlands, underscoring how differently international courts have approached the same underlying science and corporate conduct allegations.
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.